A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

LIPO-102 is under evaluation for treatment of abdominal adiposity

Phase 2

Neothetics, Inc